| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
CB1 20 nM (Ki) TRPV1
(R)-Methanandamide targets the cannabinoid receptor 1 (CB1) as a potent agonist. It shows selectivity for CB1 over CB2 receptors with Ki values of 17.9-28.3 nM for CB1 and 815-868 nM for CB2. CB1 receptors are primarily expressed in the central nervous system and are involved in pain modulation, appetite regulation, memory, and neuroprotection. As a stable chiral analog of anandamide, (R)-Methanandamide provides enhanced metabolic stability compared to the parent compound. Its effects have been observed across different organisms including mammals, fish, and certain invertebrates. |
|---|---|
| ln Vitro |
By activating both the cannabinoid (CB1) and vanilloid (TRPV1) receptors on nociceptive primary afferents, the endogenous cannabinoid (R)-Methanandamide exhibits distinct anti- and pronociceptive effects[2].
In vitro studies demonstrate that (R)-Methanandamide (AM-356) is a potent CB1 agonist with a Ki of approximately 20 nM. The compound is selective for CB1 over CB2 receptors with Ki values ranging from 17.9-28.3 nM for CB1 and 815-868 nM for CB2. It is more potent than arachidonoyl ethanolamide (anandamide). As a chiral analog of anandamide, it provides enhanced metabolic stability for studying cannabinoid receptor function. The compound is widely used in cannabinoid research to investigate CB1-mediated signaling pathways. Its effects have been characterized in various cell-based assays. |
| ln Vivo |
In vivo studies of (R)-Methanandamide have been reported in the context of cannabinoid receptor research. The compound has been used to study CB1 receptor-mediated effects in various organisms including mammals, fish, and certain invertebrates such as Hydra. As a stable chiral analog of anandamide, it provides enhanced metabolic stability for in vivo investigations. The compound has been used to study the physiological and behavioral effects of CB1 activation. Specific in vivo efficacy data in disease models are available in the literature. Further details can be found in the primary research publications.
|
| Enzyme Assay |
For CB1 receptor binding assays, cell membranes expressing CB1 receptors are prepared and incubated with radiolabeled ligands (e.g., [3H]-CP55940 or [3H]-SR141716A) and varying concentrations of (R)-Methanandamide. Non-specific binding is determined using excess unlabeled reference compound (e.g., SR141716A). Following incubation at appropriate temperature (typically 25-37°C for 60-90 minutes), bound and free radioligands are separated by rapid filtration through glass fiber filters. Filters are washed, dried, and radioactivity counted by liquid scintillation. Ki values are calculated from competitive binding curves using the Cheng-Prusoff equation. Assays are performed in triplicate with appropriate vehicle controls.
|
| Cell Assay |
For in vitro cellular assays, cells expressing CB1 or CB2 receptors (e.g., CHO cells or HEK293 cells) are cultured in appropriate media under standard conditions (37°C, 5% CO2). (R)-Methanandamide is dissolved in DMSO and diluted in culture medium to desired concentrations (typically nM to μM range). Cells are treated with compound for specified durations. Cannabinoid receptor activation is assessed by measuring downstream signaling such as inhibition of cAMP accumulation (using ELISA or FRET-based assays), activation of MAPK/ERK pathways (Western blot), or calcium flux (for Gq-coupled receptors). Each concentration is tested in replicate wells with vehicle controls and positive controls (e.g., WIN55,212-2 or CP55940).
|
| Animal Protocol |
For in vivo animal studies of (R)-Methanandamide, the compound is typically formulated in suitable vehicles (e.g., ethanol/emulphor/saline mixtures or DMSO/PEG/saline) and administered via intraperitoneal (i.p.), intravenous (i.v.), or subcutaneous (s.c.) injection. Dosing regimens vary by study objective. For behavioral studies, animals are treated with compound and tested in appropriate assays (e.g., nociception, locomotor activity, or feeding behavior). Blood and brain tissue samples may be collected for pharmacokinetic analysis. All procedures follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (R)-Methanandamide indicate it is a stable chiral analog of anandamide with enhanced metabolic stability. The compound has a molecular weight of 361.6, formula C23H39NO2, and CAS number 157182-49-5. Purity: ≥95%. Storage: typically at -20°C for powder; in solvent at -80°C. Solubility: soluble in DMSO, ethanol, and other organic solvents. The compound is more potent than anandamide. Specific pharmacokinetic parameters such as half-life, clearance, and bioavailability are reported in the primary literature.
|
| Toxicity/Toxicokinetics |
According to available safety information, (R)-Methanandamide is intended for research use only and not for human therapeutic applications. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. As a CB1 agonist, it may have psychoactive effects. No clinical toxicity data are available.
|
| References | |
| Additional Infomation |
Methanandamide is a fatty amide.
(R)-Methanandamide (AM-356) is a potent CB1 agonist with a Ki of approximately 20 nM, selective for CB1 over CB2 receptors (Ki CB1: 17.9-28.3 nM; CB2: 815-868 nM). It is a synthetic chiral analog of anandamide with enhanced metabolic stability. The compound is more potent than arachidonoyl ethanolamide (anandamide). Its effects have been observed in mammals, fish, and invertebrates. It is for research use only with no clinical development or regulatory approvals reported. |
| Molecular Formula |
C23H39NO2
|
|---|---|
| Molecular Weight |
361.56
|
| Exact Mass |
361.298
|
| CAS # |
157182-49-5
|
| PubChem CID |
6321351
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
529.0±50.0 °C at 760 mmHg
|
| Flash Point |
273.8±30.1 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.501
|
| LogP |
6.01
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
26
|
| Complexity |
436
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(N[C@@H](CO)C)=O
|
| InChi Key |
SQKRUBZPTNJQEM-FQPARAGTSA-N
|
| InChi Code |
InChI=1S/C23H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23(26)24-22(2)21-25/h7-8,10-11,13-14,16-17,22,25H,3-6,9,12,15,18-21H2,1-2H3,(H,24,26)/b8-7-,11-10-,14-13-,17-16-/t22-/m1/s1
|
| Chemical Name |
(5Z,8Z,11Z,14Z)-N-[(2R)-1-hydroxypropan-2-yl]icosa-5,8,11,14-tetraenamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7658 mL | 13.8290 mL | 27.6579 mL | |
| 5 mM | 0.5532 mL | 2.7658 mL | 5.5316 mL | |
| 10 mM | 0.2766 mL | 1.3829 mL | 2.7658 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA